Methods for performing a coronary artery bypass graft procedure

A technology for coronary artery and coronary artery disease, which can be applied to surgical drugs, devices with human tubular structures, and pharmaceutical formulations, etc., and can solve problems such as resource consumption

Inactive Publication Date: 2012-11-21
STEALTH PEPTIDES INT
View PDF12 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

CABG surgery is one of the most common surgeries performed in the world and results i

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for performing a coronary artery bypass graft procedure
  • Methods for performing a coronary artery bypass graft procedure
  • Methods for performing a coronary artery bypass graft procedure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0246] Example 1. The role of aromatic-cationic peptides in protecting rabbit models from vascular occlusion injury

[0247] The role of aromatic-cationic peptides in protecting rabbit models from vascular occlusive injury was investigated. Peptide D-Arg-2'6'-Dmt-Lys-Phe-NH is confirmed by this example 2 cardioprotective effect.

[0248] experimental method

[0249] New Zealand white rabbits were used in this study. The rabbit is male and older than 10 weeks. The environmental controls of the animal room were set to maintain a temperature of 61°F to 72°F and a relative humidity between 30% and 70%. Room temperature and humidity were recorded hourly and monitored daily. There were about 10-15 air changes per hour in the animal room. The photoperiod was 12 h light / 12 h dark (with the help of fluorescent lighting), except for necessary dose adjustments and data collection periods. Make routine daily observations. From arrival at the laboratory, approximately 180 g of ...

Embodiment 2

[0274] Example 2. The role of peptides in protecting humans from vascular occlusive injury

[0275] This example will determine the administration of D-Arg-2'6'-Dmt-Lys-Phe-NH at the time of revascularization 2 Does it limit infarct size during acute myocardial infarction.

[0276] research group. Men and women 18 years of age or older who presented to the hospital after the onset of chest pain and had a clinical decision to treat them with revascularization (eg, PCI or thrombolysis) were eligible for inclusion. Patients can be STEMI (ST-segment elevation myocardial infarction) or non-STEMI. A STEMI patient will have symptoms suggestive of a cut off of blood supply to the heart muscle and conditioned by the typical heart attack pattern where the patient's ECG shows ST-segment elevation. Therefore, the diagnosis is based solely on symptoms, clinical examination, and ECG changes. In the case of a non-ST-segment elevation heart attack, the symptoms of chest pain can be the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof, and performing a coronary artery bypass graft procedure on the subject.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Patent Application No. 61 / 291,699, filed December 31, 2009, U.S. Provisional Patent Application No. 61 / 363,138, filed July 9, 2010, and U.S. Provisional Patent Application No. 61 / 363,138, filed October 26, 2010 Priority to U.S. Provisional Patent Application No. 406,713, which is hereby incorporated by reference in its entirety. technical field [0003] The present invention relates generally to compositions and methods for treating obstructive coronary artery disease using coronary artery bypass graft (CABG) surgery. Specifically, the methods involve administering an effective amount of an aromatic-cationic peptide prior to, during, and / or after CABG surgery. Background technique [0004] The following descriptions are provided for the reader's convenience. None of the information provided or references cited is admitted to be prior art to the present invention. [0005] Cor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/07A61P9/10
CPCA61K38/07A61K38/06A61P13/12A61P25/00A61P41/00A61P43/00A61P9/10A61K9/0019A61M5/14A61F2/06A61M2210/125A61M39/08
Inventor 肯尼斯·博罗D·特拉维斯·威尔逊
Owner STEALTH PEPTIDES INT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap